Elyxyb is a drug owned by Scilex Pharmaceuticals Inc. It is protected by 6 US drug patents filed from 2020 to 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 27, 2036. Details of Elyxyb's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9949990 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
| US9572819 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
| US10376527 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
| US10722456 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
| US10799517 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
| US9795620 | Oral composition of celecoxib for treatment of pain |
May, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Elyxyb's patents.
Latest Legal Activities on Elyxyb's Patents
Given below is the list of recent legal activities going on the following patents of Elyxyb.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10799517 |
| Surcharge for Late Payment, Large Entity | 26 Jun, 2024 | US10799517 |
| Maintenance Fee Reminder Mailed Critical | 03 Jun, 2024 | US10799517 |
| Change in Power of Attorney (May Include Associate POA) Critical | 01 Apr, 2024 | US10799517 |
| Change in Power of Attorney (May Include Associate POA) Critical | 01 Apr, 2024 | US10722456 |
| Email Notification Critical | 01 Apr, 2024 | US10722456 |
| Email Notification Critical | 01 Apr, 2024 | US10799517 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Mar, 2024 | US10376527 |
| Email Notification Critical | 29 Mar, 2024 | US10376527 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Mar, 2024 | US9572819 |
FDA has granted several exclusivities to Elyxyb. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Elyxyb, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Elyxyb.
Exclusivity Information
Elyxyb holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Elyxyb's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2023 |
US patents provide insights into the exclusivity only within the United States, but Elyxyb is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Elyxyb's family patents as well as insights into ongoing legal events on those patents.
Elyxyb's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Elyxyb's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 27, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Elyxyb Generic API suppliers:
Celecoxib is the generic name for the brand Elyxyb. 24 different companies have already filed for the generic of Elyxyb, with Watson Labs Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Elyxyb's generic
Alternative Brands for Elyxyb
Elyxyb which is used for treating acute migraine in adults., has several other brand drugs in the same treatment category and using the same active ingredient (Celecoxib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Celecoxib. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Celecoxib, Elyxyb's active ingredient. Check the complete list of approved generic manufacturers for Elyxyb
About Elyxyb
Elyxyb is a drug owned by Scilex Pharmaceuticals Inc. It is used for treating acute migraine in adults. Elyxyb uses Celecoxib as an active ingredient. Elyxyb was launched by Scilex Pharms in 2020.
Approval Date:
Elyxyb was approved by FDA for market use on 05 May, 2020.
Active Ingredient:
Elyxyb uses Celecoxib as the active ingredient. Check out other Drugs and Companies using Celecoxib ingredient
Treatment:
Elyxyb is used for treating acute migraine in adults.
Dosage:
Elyxyb is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 25MG/ML | SOLUTION | Prescription | ORAL |